Perspective Therapeutics
Stock Forecast, Prediction & Price Target
Perspective Therapeutics (CATX) stock Price Target by analysts
$21
Potential upside: 517.64%
Perspective Therapeutics price prediction
What is Perspective Therapeutics stock analysts` prediction?
Perspective Therapeutics stock forecast: Based on 3 Wall Street analysts` predicted price targets for Perspective Therapeutics in the last 3 months, the avarage price target is $21, with a high forecast of $NaN. The average price target represents a 517.64% change from the last price of $3.4.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Perspective Therapeutics stock Price Target by analysts
Full breakdown of analysts given Perspective Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
David Dai UBS | 0% 0/1 | 11 months ago | $20 488.23% upside | $11.69 | StreetInsider | Previous targets (0) |
Jeff Jones Oppenheimer | 0% 0/3 | 12 months ago | $22 547.05% upside | $12.66 | StreetInsider | Previous targets (2) |
Nicole Germino Truist Financial | 0% 0/1 | about 1 year ago | $21 517.64% upside | $12.28 | StreetInsider | Previous targets (0) |
Alec Stranahan Bank of America Securities | 0% 0/1 | about 1 year ago | $24 605.88% upside | $12.82 | TheFly | Previous targets (0) |
Jeff Jones Oppenheimer | 0% 0/3 | over 1 year ago | $19 458.82% upside | $11.93 | StreetInsider | Previous targets (2) |
Gregory Renza RBC Capital | 0% 0/1 | over 1 year ago | $3 -11.76% downside | $1.15 | StreetInsider | Previous targets (0) |
Jeff Jones Oppenheimer | 0% 0/3 | over 1 year ago | $2 -41.17% downside | $1.57 | StreetInsider | Previous targets (2) |
Perspective Therapeutics Financial Estimates
Perspective Therapeutics Revenue Estimates
Perspective Therapeutics EBITDA Estimates
Perspective Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 6/30/2022 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 6/30/2026 | 12/31/2026 | 12/31/2027 |
Revenue
% change YoY
| $10.79M N/A | $7.10M -34.19% | $1.43M -79.81% | Avg: $321.4K Low: $316.22K High: $339.75K avg. -77.58% | Avg: $11.17M Low: $11.17M High: $11.17M avg. 3377.28% | Avg: $420.25K Low: $413.48K High: $444.24K avg. -96.23% | Avg: $28.68M Low: $28.22M High: $30.32M avg. 6725.93% |
Net Income
% change YoY
| $-7.15M N/A | $-14.67M -105.08% | $-46.50M -217.02% | Avg: $-64.28M Low: $-198.94M High: $-99.47M avg. -38.22% | Avg: $-38.52M Low: $-19.87M High: $-19.87M avg. 40.07% | Avg: $-68.16M Low: $-198.94M High: $-113.68M avg. -76.93% | Avg: $-171.23M Low: $-183.94M High: $-167.64M avg. -151.20% |
EBITDA
% change YoY
| $-7.39M N/A | $-14.83M -100.75% | $-39.96M -169.30% | Avg: $-199.88K Low: $-211.30K High: $-196.66K avg. 99.49% | Avg: $-6.95M Low: $-6.95M High: $-6.95M avg. -3377.28% | Avg: $-261.36K Low: $-276.29K High: $-257.15K avg. 96.23% | Avg: $-17.84M Low: $-18.85M High: $-17.55M avg. -6725.94% |
EPS
% change YoY
| -$0.05 N/A | -$0.1 -98.41% | -$1.4 -1299.99% | Avg: -$1.06 Low: -$1.4 High: -$0.7 avg. 24.28% | Avg: -$0.14 Low: -$0.14 High: -$0.14 avg. 86.79% | Avg: -$1.06 Low: -$1.4 High: -$0.8 avg. -653.57% | Avg: -$1.21 Low: -$1.29 High: -$1.18 avg. -14.21% |
Operating Expenses
% change YoY
| $12.00M N/A | $17.42M 45.13% | $42.37M 143.17% | Avg: $340.65K Low: $335.17K High: $360.11K avg. -99.19% | Avg: $9.60M Low: $9.60M High: $9.60M avg. 2720.59% | Avg: $445.43K Low: $438.25K High: $470.86K avg. -95.36% | Avg: $30.40M Low: $29.91M High: $32.14M avg. 6725.93% |
FAQ
What is Perspective Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of -56.57% in 2025-2027.
We have gathered data from 6 analysts. Their low estimate is -198.94M, average is -64.28M and high is -99.47M.
What is Perspective Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 2482.34% in 2025-2027.
We have gathered data from 5 analysts. Their low revenue estimate is $316.22K, average is $321.4K and high is $339.75K.
What is Perspective Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of -139.17% in 2025-2027.
We have gathered data from 6 analysts. Their low earnings per share estimate is -$1.4, average is -$1.06 and high is $-0.7.
What is the best performing analyst?
In the last twelve months 3 analysts have been covering Perspective Therapeutics stock. The most successful analyst is David Dai.